GSA Capital Partners LLP Invests $322,000 in GeneDx Holdings Corp. (NASDAQ:WGS)

GSA Capital Partners LLP acquired a new position in GeneDx Holdings Corp. (NASDAQ:WGS) during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 7,577 shares of the company’s stock, valued at approximately $322,000.

Other hedge funds also recently made changes to their positions in the company. Acadian Asset Management LLC purchased a new position in shares of GeneDx in the second quarter worth approximately $34,000. nVerses Capital LLC purchased a new position in shares of GeneDx in the second quarter worth approximately $50,000. CWM LLC purchased a new position in shares of GeneDx in the third quarter worth approximately $89,000. SG Americas Securities LLC purchased a new position in shares of GeneDx in the third quarter worth approximately $198,000. Finally, Palumbo Wealth Management LLC purchased a new position in shares of GeneDx in the third quarter worth approximately $287,000. Institutional investors and hedge funds own 61.72% of the company’s stock.

Insider Buying and Selling at GeneDx

In other news, Director Jason Ryan sold 31,510 shares of the business’s stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $71.28, for a total value of $2,246,032.80. Following the completion of the sale, the director now directly owns 15,490 shares in the company, valued at approximately $1,104,127.20. The trade was a 67.04 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder School Of Medicine At Mo Icahn sold 126,782 shares of the business’s stock in a transaction on Monday, November 18th. The stock was sold at an average price of $70.78, for a total transaction of $8,973,629.96. Following the completion of the sale, the insider now owns 2,719,692 shares of the company’s stock, valued at $192,499,799.76. The trade was a 4.45 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 1,097,090 shares of company stock worth $81,094,171 over the last ninety days. 27.30% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several research firms recently commented on WGS. BTIG Research raised their price target on shares of GeneDx from $35.00 to $45.00 and gave the stock a “buy” rating in a report on Wednesday, July 31st. Wells Fargo & Company raised their price target on shares of GeneDx from $34.00 to $75.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 30th. Craig Hallum raised their price target on shares of GeneDx from $70.00 to $95.00 and gave the stock a “buy” rating in a report on Wednesday, October 30th. TD Cowen raised their price target on shares of GeneDx from $46.00 to $50.00 and gave the stock a “buy” rating in a report on Wednesday, July 31st. Finally, The Goldman Sachs Group raised their price target on shares of GeneDx from $54.00 to $70.00 and gave the stock a “neutral” rating in a report on Wednesday, October 30th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $59.33.

GeneDx Price Performance

NASDAQ WGS opened at $78.71 on Friday. The company has a quick ratio of 2.27, a current ratio of 2.40 and a debt-to-equity ratio of 0.25. The stock has a market capitalization of $2.16 billion, a PE ratio of -25.31 and a beta of 2.11. The company has a 50 day moving average price of $59.61 and a two-hundred day moving average price of $39.55. GeneDx Holdings Corp. has a 12-month low of $1.41 and a 12-month high of $89.11.

GeneDx (NASDAQ:WGS) last posted its earnings results on Tuesday, October 29th. The company reported $0.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.25. The firm had revenue of $76.90 million during the quarter, compared to analysts’ expectations of $64.98 million. GeneDx had a negative net margin of 31.25% and a negative return on equity of 13.35%. The company’s revenue was up 44.3% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.82) earnings per share. As a group, equities analysts predict that GeneDx Holdings Corp. will post -0.24 earnings per share for the current fiscal year.

GeneDx Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.